113209-68-0

Basic information

• Product Name: 7-Fluoro-4-chromanone
• Synonyms: 7-FLUOROCHROMAN-4-ONE;4H-1-BENZOPYRAN-4-ONE, 7-FLUORO-2,3-DIHYDRO-;7-Fluoro-4-chromanone;6-fluoro-3,4-dihydro-2H-1-benzopyran-4-one;7-FluorochroMan-4-one, May contain up to 15% 5-isoMer, 98% (suM of isoMers);7-Fluoro-2,3-dihydro-4H-chromen-4-one;7-Fluorochroman-4-one, sum of isomers
• CAS NO: 113209-68-0
• Molecular Formula: C₉H₇FO₂
• Molecular Weight: 166.15
• Mol File: 113209-68-0.mol
• Article Data: 13

Chemical Properties

• Melting Point: 46-50℃
• Boiling Point: 281.9 °C at 760 mmHg
• Flash Point: 120.5 °C
• Appearance: /
• Density: 1.297 g/cm³
• Vapor Pressure: 0.00347mmHg at 25°C
• Refractive Index: 1.539
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 7-Fluoro-4-chromanone(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Fluoro-4-chromanone(113209-68-0)
• EPA Substance Registry System: 7-Fluoro-4-chromanone(113209-68-0)

Safety Data

• Hazard Codes: Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 113209-68-0(Hazardous Substances Data)

Usage

General Description

7-Fluoro-4-chromanone is a chemical compound with the molecular formula C10H7FO2. It is a fluorinated derivative of 4-chromanone, which is a heterocyclic compound commonly found in natural products. 7-Fluoro-4-chromanone has potential applications in pharmaceutical research and drug discovery due to its structural properties and potential pharmacological activities. It has been studied for its potential anti-inflammatory, antioxidant, and neuroprotective effects. Additionally, it may have potential applications in the development of novel drugs for the treatment of various diseases and conditions. Overall, 7-Fluoro-4-chromanone is a compound of interest in the field of medicinal chemistry and drug development.

InChI:InChI=1/C9H7FO2/c10-6-1-2-7-8(11)3-4-12-9(7)5-6/h1-2,5H,3-4H2

Upstream product

• 590-92-1 3-Bromopropionic acid 
• 372-20-3 3-fluorophenol 
• 844648-05-1 3-(3-fluorophenoxy)propanenitrile 
• 1579-78-8 3-(4-fluoro-phenoxy)propionic acid 
• 104413-57-2 3-(4-fluorophenoxy)-1-propanol 
• 371-41-5 4-Fluorophenol 
• 133077-42-6 3-(3-fluorophenoxy)propanoic acid 
• 10026-13-8 phosphorus pentachloride 
• 87411-27-6 3-(3-fluorophenoxy)propanecarboxylic acid 

Downstream Products

• 895570-82-8 7-phenylsulfanyl-chroman-4-one 
• 1202887-91-9 6-cyano-7-(4-(2',3'-dimethylbiphenyl-3-ylcarbamoyl)phenoxy)chroman-4-carboxylic acid 
• 1269508-49-7 methyl 6-cyano-7-(4-(2',3'-dimethylbiphenyl-3-ylcarbamoyl)phenoxy)chroman-4-carboxylate 
• 1202890-41-2 methyl 6-cyano-7-(4-(4'-methylbiphenyl-3-ylcarbamoyl)phenoxy)chroman-4-carboxylate 
• 1202887-89-5 6-cyano-7-(4-(4'-methylbiphenyl-3-ylcarbamoyl)phenoxy)chroman-4-carboxylic acid 
• 1202887-32-8 7-(4-((2-(4-chlorophenyl)cyclopropyl)carbamoyl)phenoxy)-6-cyano-3,4-dihydro-2H-chromene-4-carboxylic acid 
• 1202890-21-8 methyl 7-(4-((2-(4-chlorophenyl)cyclopropyl)carbamoyl)phenoxy)-6-cyano-3,4-dihydro-2H-chromene-4-carboxylate 
• 1202890-26-3 methyl 7-(4-(biphenyl-3-ylcarbamoyl)phenoxy)-6-cyanochroman-4-carboxylate 
• 1202889-79-9 methyl 7-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-6-cyano-4-methylchroman-4-carboxylate 
• 1202886-83-6 6-cyano-7-(4-(4-chlorophenethylcarbamoyl)phenoxy)chroman-4-carboxylic acid 
• 1202887-48-6 7-(4-(biphenyl-3-ylcarbamoyl)phenoxy)-6-cyanochroman-4-carboxylic acid 
• 1202886-89-2 7-(4-(4-chlorobenzyloxycarbamoyl)phenoxy)-6-cyanochroman-4-carboxylic acid 
• 1202889-77-7 methyl 7-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-6-cyanochroman-4-carboxylate 
• 1202886-90-5 6-cyano-7-(4-(3,4-dichlorophenylcarbamoyl)phenoxy)chroman-4-carboxylic acid 

Relevant articles and documents

Exploiting the Chromone Scaffold for the Development of Inhibitors of Corticosteroid Biosynthesis

The inhibition of corticosteroid biosynthesis could be considered as an emerging strategy to reduce their abnormally high levels, and in this framework CYP11B1 and CYP11B2 represent the most promising targets. In continuing our studies on flavonoid-like scaffolds as privileged structures in medicinal chemistry, in this paper we describe a small library of pyridyl- and imidazolylmethylchromones as potential inhibitors of these enzymes. Testing results proved that position 3 of the chromone scaffold is the most favorable for the introduction of the heme-coordinating heterocycles and, among them, the 4-imidazolyl moiety is the most convenient for the interaction with the heme iron of the selected cytochromes. A low nanomolar inhibitor of CYP11B1 (5c) was obtained, endowed with reasonable selectivity toward CYP11B2 and able to better discriminate with respect to CYP17 and CYP19.

Steroid synthase inhibitors and therapeutic application thereof

The invention discloses a steroid synthase inhibitor and treatment application thereof, and belongs to the field of medicines. The compound capable of being used as the medicine has the effect of inhibiting steroid synthase, is high in inhibition rate and

Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application

The design and synthesis of novel HIV-1 protease inhibitors (PIs) (1-22), which display high potency against HIV-1 wild-type and multi-PI-resistant HIV-mutant clinical isolates, is described. Lead optimization was initiated from compound 1, a Phe-Phe hydroxyethylene peptidomimetic PI, and was directed towards the discovery of new PIs suitable for a long-acting (LA) injectable drug application. Introducing a heterocyclic 6-methoxy-3-pyridinyl or a 6-(dimethylamino)-3-pyridinyl moiety (R3) at the para-position of the P1′ benzyl fragment generated compounds with antiviral potency in the low single digit nanomolar range. Halogenation or alkylation of the metabolic hot spots on the various aromatic rings resulted in PIs with high stability against degradation in human liver microsomes and low plasma clearance in rats. Replacing the chromanolamine moiety (R1) in the P2 protease binding site by a cyclopentanolamine or a cyclohexanolamine derivative provided a series of high clearance PIs (16-22) with EC50s on wild-type HIV-1 in the range of 0.8-1.8 nM. PIs 18 and 22, formulated as nanosuspensions, showed gradual but sustained and complete release from the injection site over two months in rats, and were therefore identified as interesting candidates for a LA injectable drug application for treating HIV/AIDS.